Mutated factor X polypeptides and uses thereof for the treatment of haemophilia
US-10655119-B2 · May 19, 2020 · US
Mutated factor X polypeptides and uses thereof for the treatment of haemophilia
US11085032B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11085032-B2 |
| Application number | US-202016846939-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 13, 2020 |
| Priority date | Jul 25, 2015 |
| Publication date | Aug 10, 2021 |
| Grant date | Aug 10, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 401 or 408 is mutated.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating haemophilia in a subject in need thereof comprising; administering to the subject a therapeutically effective amount of a mammalian mutated Factor X polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 which comprises a heavy chain, wherein the amino acid residue at position 441 and/or position 448 is mutated, and wherein said Factor X polypeptide is not inactivated by a Factor X inhibitor selected from the group consisting of antithrombin (AT), tissue pathway inhibitor (TFPI) and alloantibodies to Factor X.
Assignees
Inventors
Classifications
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
Coagulation factor Xa (3.4.21.6) · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
- C12N9/6432Primary
Coagulation factor Xa (3.4.21.6) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11085032B2 cover?
- The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 401 or 408 is mutated.
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med, Univ Paris—Sud, Univ Paris Diderot—Paris 7, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification C12N9/6432. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).